PE20142356A1 - Metodo de tratamiento de las dermatosis sensibles a los esteroides - Google Patents

Metodo de tratamiento de las dermatosis sensibles a los esteroides

Info

Publication number
PE20142356A1
PE20142356A1 PE2014001697A PE2014001697A PE20142356A1 PE 20142356 A1 PE20142356 A1 PE 20142356A1 PE 2014001697 A PE2014001697 A PE 2014001697A PE 2014001697 A PE2014001697 A PE 2014001697A PE 20142356 A1 PE20142356 A1 PE 20142356A1
Authority
PE
Peru
Prior art keywords
chloro
methyl
steroid
treatment
sensitive dermatoses
Prior art date
Application number
PE2014001697A
Other languages
English (en)
Spanish (es)
Inventor
Pankaj Agarwal
Vinod Kumar
Quing Xie
Original Assignee
Glaxosmithkline Intellectual Property (N 2) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142356(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Intellectual Property (N 2) Limited filed Critical Glaxosmithkline Intellectual Property (N 2) Limited
Publication of PE20142356A1 publication Critical patent/PE20142356A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2014001697A 2012-04-24 2013-04-22 Metodo de tratamiento de las dermatosis sensibles a los esteroides PE20142356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PE20142356A1 true PE20142356A1 (es) 2015-01-30

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001697A PE20142356A1 (es) 2012-04-24 2013-04-22 Metodo de tratamiento de las dermatosis sensibles a los esteroides

Country Status (26)

Country Link
US (2) US20150087683A1 (https=)
EP (1) EP2841053A1 (https=)
JP (1) JP2015514792A (https=)
KR (1) KR20150010943A (https=)
CN (1) CN104302275A (https=)
AR (1) AR090795A1 (https=)
AU (1) AU2013254849B2 (https=)
BR (1) BR112014026706A2 (https=)
CA (1) CA2873751A1 (https=)
CL (1) CL2014002861A1 (https=)
CO (1) CO7111283A2 (https=)
CR (1) CR20140491A (https=)
DO (1) DOP2014000238A (https=)
EA (1) EA201491914A1 (https=)
HK (1) HK1201726A1 (https=)
IL (1) IL235159A0 (https=)
MX (1) MX2014012904A (https=)
NZ (1) NZ628394A (https=)
PE (1) PE20142356A1 (https=)
PH (1) PH12014502400A1 (https=)
SG (1) SG11201406409VA (https=)
TW (1) TW201347758A (https=)
UA (1) UA113875C2 (https=)
UY (1) UY34762A (https=)
WO (1) WO2013160222A1 (https=)
ZA (1) ZA201407345B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E(IgE)介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
AU2006235314B2 (en) * 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN102405047B (zh) * 2009-01-30 2014-07-09 葛兰素史密斯克莱有限责任公司 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
JP2013507382A (ja) * 2009-10-08 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
AR090795A1 (es) 2014-12-10
CL2014002861A1 (es) 2015-01-16
MX2014012904A (es) 2014-11-21
EA201491914A1 (ru) 2015-01-30
AU2013254849A1 (en) 2014-11-06
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26
TW201347758A (zh) 2013-12-01
CN104302275A (zh) 2015-01-21
CR20140491A (es) 2014-12-22
ZA201407345B (en) 2015-11-25
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
AU2013254849B2 (en) 2016-05-26
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
PH12014502400A1 (en) 2015-01-12
KR20150010943A (ko) 2015-01-29
CA2873751A1 (en) 2013-10-31
EP2841053A1 (en) 2015-03-04
DOP2014000238A (es) 2014-12-15
IL235159A0 (en) 2014-12-31
WO2013160222A1 (en) 2013-10-31
UY34762A (es) 2013-11-29
JP2015514792A (ja) 2015-05-21
NZ628394A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX360495B (es) Derivados deuterados de ruxolitinib.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
PE20151023A1 (es) Triazolopirazinas
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
MX381890B (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos
CR20190073A (es) FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
MX362485B (es) Nuevos inhibidores de rock.
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2020005735A (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
CU20160140A7 (es) CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed